Objective To explore the application value of angiotensin Ⅱ(ATⅡ), neuropeptide Y(NPY), insulin-like growth factor 1(IGF-1) and high sensitive C-reaction protein(hs-CRP) levels in evaluation of the severity of coronary heart disease(CHD).

Methods The plasma ATⅡ, NPY, IGF-1 and hs-CRP levels in 157 patients with CHD including 51 cases with stable angina(SA), 45 cases with unstable angina(USA) and 61 cases with acute myocardial infraction(AMI) were measured by radioimmunoassay, enzyme immunoassay and high sensitive enzyme immunoassay and were compared with 60 health controls.

Results The plasma ATⅡ level in 157 patients with CHD was significantly higher than those in 60 controls(t_{SA ATⅡ}=2.257, P < 0.05;t_{USA ATⅡ}=3.018, P < 0.01;t_{AMI ATⅡ}=4.143, P < 0.001). The plasma NPY level in 157 patients with CHD was higher than those in 60 controls(t_{SA NPY}=1.413, P > 0.05;t_{USA NPY}=2.148, P < 0.05;t_{AMI NPY}=3.068, P < 0.01), but there were no significant difference between SA patients and the 60 conrols. The plasma IGF-1 level in 157 patients with CHD was significantly higher than those in 60 controls(t_{SA IGF-1}=2.121, P < 0.05;t_{USA IGF-1}=2.937, P < 0.01;t_{AMI IGF-1}=4.217, P < 0.001). The plasma hs-CRP level in 157 patients with CHD was significantly higher than those in 60 controls(t_{SA hs-CRP}=2.095, P < 0.05;t_{USA hs-CRP}=2.867, P < 0.01;t_{AMI hs-CRP}=4.349, P < 0.001). The four plasma biomarkers were increased with severity of CHD.

Conclusion The plasma ATⅡ, NPY, IGF-1 and hs-CRP levels were valuable indexes for judging the severity of patients with CHD, and could be used for follow-up.